{"questions":[{"id":"open_question-27d9a494-acea-46e5-95a3-a9ee68027a87","artifact_type":"open_question","title":"How does age affect neurotrophin therapy response?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.985940+00:00","updated_at":"2026-04-26T03:27:56.985940+00:00"},{"id":"open_question-b7651f5b-1fcc-46e9-8110-4d69b06c42d9","artifact_type":"open_question","title":"What molecular pathways link different proteinopathies?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.820570+00:00","updated_at":"2026-04-26T03:29:35.820570+00:00"},{"id":"open_question-93c6bab9-f413-4a21-b43a-03531ac562fe","artifact_type":"open_question","title":"Can we prevent secondary proteinopathy after primary diagnosis?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.768417+00:00","updated_at":"2026-04-26T03:29:35.768417+00:00"},{"id":"open_question-a5322346-17bb-4f1b-8fab-ba9e702309ba","artifact_type":"open_question","title":"What determines which protein pathology develops first?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.708947+00:00","updated_at":"2026-04-26T03:29:35.708947+00:00"},{"id":"open_question-ecb80fe3-243b-4929-9554-1892c5c2f4a8","artifact_type":"open_question","title":"How do we model co-pathology in experimental systems?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:29:35.874758+00:00","updated_at":"2026-04-26T03:29:35.874758+00:00"},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-232de8b4","artifact_type":"open_question","title":"Strain-specific targeting","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-4892d91a","artifact_type":"open_question","title":"Early intervention","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-24c5bcee","artifact_type":"open_question","title":"Biomarker development","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-adb20a00","artifact_type":"open_question","title":"Combination approaches","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-e7abc851-8ce3-480b-835a-369d76c86bc6","artifact_type":"open_question","title":"What is the optimal timing for neurotrophin intervention relative to disease stage?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.622081+00:00","updated_at":"2026-04-26T03:27:56.622081+00:00"},{"id":"open_question-dc094973-c93f-4225-8d1f-ccd5005c66d0","artifact_type":"open_question","title":"Can combination therapy (GDNF + anti-α-syn) provide synergistic benefits?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.682470+00:00","updated_at":"2026-04-26T03:27:56.682470+00:00"},{"id":"open_question-b4513284-52f5-4217-a4d1-ef2ddf04c626","artifact_type":"open_question","title":"How do genetic subtypes (LRRK2, GBA, SNCA) affect neurotrophin response?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.741566+00:00","updated_at":"2026-04-26T03:27:56.741566+00:00"},{"id":"open_question-242876d5-1f07-4666-82e2-2afe3571a457","artifact_type":"open_question","title":"What are the long-term safety implications of sustained GDNF expression?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.802127+00:00","updated_at":"2026-04-26T03:27:56.802127+00:00"},{"id":"open_question-65be8c41-e052-42d0-98f4-bfa504713186","artifact_type":"open_question","title":"Can peripheral biomarkers predict CNS neurotrophin deficiency?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.860753+00:00","updated_at":"2026-04-26T03:27:56.860753+00:00"},{"id":"open_question-6471b210-0fa3-430b-a0ba-af201961fc4a","artifact_type":"open_question","title":"What is the minimum effective dose for different delivery methods?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:56.922309+00:00","updated_at":"2026-04-26T03:27:56.922309+00:00"},{"id":"open_question-4b9da982-2b1b-4bf5-b50c-0b058ce8fa22","artifact_type":"open_question","title":"Can biomarker panels identify ideal candidates for specific therapies?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.041296+00:00","updated_at":"2026-04-26T03:27:57.041296+00:00"},{"id":"open_question-32b096d5-30df-4611-96ef-5f5ea86add77","artifact_type":"open_question","title":"Does SG dysfunction precede alpha-synuclein pathology in humans?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.658863+00:00","updated_at":"2026-04-26T03:27:57.658863+00:00"},{"id":"open_question-173a4067-8ac7-4769-b5a0-e0bb515cb9ac","artifact_type":"open_question","title":"Can SG modulation slow disease progression in PD models?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.711408+00:00","updated_at":"2026-04-26T03:27:57.711408+00:00"},{"id":"open_question-4dcfc292-0919-476f-a8e2-400cef297d14","artifact_type":"open_question","title":"What are the specific vulnerabilities of dopaminergic neurons to SG pathology?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.767214+00:00","updated_at":"2026-04-26T03:27:57.767214+00:00"},{"id":"open_question-5a295a20-6e17-4167-8ec1-8eed0e04a9be","artifact_type":"open_question","title":"How do genetic risk factors (LRRK2, GBA, SNCA) interact with SG pathways?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.835942+00:00","updated_at":"2026-04-26T03:27:57.835942+00:00"},{"id":"open_question-8b0507c5-dc4a-4d98-af36-8ed128f06ea6","artifact_type":"open_question","title":"Can biomarkers detect SG dysfunction in living patients?","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T03:27:57.914376+00:00","updated_at":"2026-04-26T03:27:57.914376+00:00"},{"id":"open_question-hypotheses-mlsm-axis-parkinsons-97cf375b","artifact_type":"open_question","title":"Structural Biology","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-mlsm-axis-parkinsons-0c84ae5a","artifact_type":"open_question","title":"Human Biomarkers","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-mlsm-axis-parkinsons-d831af3d","artifact_type":"open_question","title":"Genetic Stratification","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-mlsm-axis-parkinsons-78ad4d19","artifact_type":"open_question","title":"Combination Therapy","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi-3d692c59","artifact_type":"open_question","title":"Improved dual-pathology models","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi-9c4ec64b","artifact_type":"open_question","title":"Biomarker-driven trials","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi-adb20a00","artifact_type":"open_question","title":"Combination approaches","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-amyloid-plaque-neurofibrillary-tangle-depositi-30221c46","artifact_type":"open_question","title":"Precision medicine","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-neurotrophin-signaling-dysfunction-parkinsons-f53daf79","artifact_type":"open_question","title":"Engineered neurotrophins","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-neurotrophin-signaling-dysfunction-parkinsons-abaecc63","artifact_type":"open_question","title":"Exosome-based delivery","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-neurotrophin-signaling-dysfunction-parkinsons-b21d62bf","artifact_type":"open_question","title":"Gene editing","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-neurotrophin-signaling-dysfunction-parkinsons-3a62166e","artifact_type":"open_question","title":"Biomarker-driven patient selection","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-neurotrophin-signaling-dysfunction-parkinsons-f90554c5","artifact_type":"open_question","title":"Small molecule Trk modulators","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-neurotrophin-signaling-dysfunction-parkinsons-0f4e8a36","artifact_type":"open_question","title":"Nanoparticle encapsulation","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-5215b909","artifact_type":"open_question","title":"Single-cell proteomics","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-e3ccc829","artifact_type":"open_question","title":"Spatial transcriptomics","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-3e2fbe2a","artifact_type":"open_question","title":"Cryo-EM structures","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-740246c3","artifact_type":"open_question","title":"Systems biology","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-5c85ade1","artifact_type":"open_question","title":"Common pathway targeting","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-adb20a00","artifact_type":"open_question","title":"Combination approaches","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-9c4ec64b","artifact_type":"open_question","title":"Biomarker-driven trials","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"},{"id":"open_question-hypotheses-hyp_575716-615885f2","artifact_type":"open_question","title":"Stage-specific interventions","quality_score":0.5,"metadata":{},"created_at":"2026-04-26T00:54:30.013560+00:00","updated_at":"2026-04-26T00:54:30.013560+00:00"}],"total":43,"limit":100,"offset":0,"returned":43,"sort":"importance_elo","field":"hypotheses"}